Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
11
YCBD Quote, Financials, Valuation and Earnings
Last price:
$0.79
Seasonality move
:
-14.33%
Day range:
$0.81 - $0.90
52-week range:
$0.47 - $3.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.26x
P/B ratio:
0.95x
Volume:
394.9K
Avg. volume:
1.4M
1-year change:
-74.48%
Market cap:
$8.5M
Revenue:
$19.2M
EPS (TTM):
-$2.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
$4.9M | -- | 11.43% | -- | $2.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
ELTP
Elite Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
GKOS
Glaukos Corp.
|
$137M | -$0.20 | 28.42% | -14.86% | $134.79 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
$0.81 | $2.00 | $8.5M | -- | $0.00 | 0% | 0.26x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.81 | $31.80 | $3.9B | 9.97x | $0.00 | 0% | 3.61x |
|
ELTP
Elite Pharmaceuticals, Inc.
|
$0.39 | -- | $421.3M | 18.03x | $0.00 | 0% | 3.08x |
|
GKOS
Glaukos Corp.
|
$121.12 | $134.79 | $7B | -- | $0.00 | 0% | 13.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.43 | $0.85 | $37.4M | 5.05x | $4.00 | 0% | 1.10x |
|
SAVA
Cassava Sciences, Inc.
|
$2.32 | $8.00 | $112.1M | -- | $0.00 | 0% | 2.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
6.18% | 0.621 | 4.36% | 1.84x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ELTP
Elite Pharmaceuticals, Inc.
|
7.01% | 3.643 | 1.15% | 5.38x |
|
GKOS
Glaukos Corp.
|
13.97% | 0.983 | 1.64% | 3.91x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -1.682 | 8.08% | 1.85x |
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.470 | -- | 2.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
$2.8M | -$286.3K | -39.12% | -47.18% | -5.71% | -$977.3K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ELTP
Elite Pharmaceuticals, Inc.
|
$12.6M | $9M | 67.69% | 77.64% | 28.53% | -$5.5M |
|
GKOS
Glaukos Corp.
|
$111.4M | -$27M | -22.09% | -25.22% | -18.87% | -$12.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
cbdMD, Inc. vs. Competitors
-
Which has Higher Returns YCBD or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -5.64% compared to cbdMD, Inc.'s net margin of 96.33%. cbdMD, Inc.'s return on equity of -47.18% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.54.93% -$0.04 $9.6M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About YCBD or ACAD?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 146.31%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 39.41%. Given that cbdMD, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe cbdMD, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is YCBD or ACAD More Risky?
cbdMD, Inc. has a beta of 2.127, which suggesting that the stock is 112.722% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock YCBD or ACAD?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or ACAD?
cbdMD, Inc. quarterly revenues are $5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. cbdMD, Inc.'s net income of -$283.1K is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.26x versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.26x -- $5M -$283.1K ACADACADIA Pharmaceuticals, Inc.3.61x 9.97x $284M $273.6M
-
Which has Higher Returns YCBD or ELTP?
Elite Pharmaceuticals, Inc. has a net margin of -5.64% compared to cbdMD, Inc.'s net margin of 58.86%. cbdMD, Inc.'s return on equity of -47.18% beat Elite Pharmaceuticals, Inc.'s return on equity of 77.64%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.54.93% -$0.04 $9.6M ELTPElite Pharmaceuticals, Inc.39.78% $0.01 $86.4M -
What do Analysts Say About YCBD or ELTP?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 146.31%. On the other hand Elite Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 922.5%. Given that Elite Pharmaceuticals, Inc. has higher upside potential than cbdMD, Inc., analysts believe Elite Pharmaceuticals, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 ELTPElite Pharmaceuticals, Inc.0 0 0 -
Is YCBD or ELTP More Risky?
cbdMD, Inc. has a beta of 2.127, which suggesting that the stock is 112.722% more volatile than S&P 500. In comparison Elite Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.003%.
-
Which is a Better Dividend Stock YCBD or ELTP?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elite Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Elite Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or ELTP?
cbdMD, Inc. quarterly revenues are $5M, which are smaller than Elite Pharmaceuticals, Inc. quarterly revenues of $31.6M. cbdMD, Inc.'s net income of -$283.1K is lower than Elite Pharmaceuticals, Inc.'s net income of $18.6M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Elite Pharmaceuticals, Inc.'s PE ratio is 18.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.26x versus 3.08x for Elite Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.26x -- $5M -$283.1K ELTPElite Pharmaceuticals, Inc.3.08x 18.03x $31.6M $18.6M
-
Which has Higher Returns YCBD or GKOS?
Glaukos Corp. has a net margin of -5.64% compared to cbdMD, Inc.'s net margin of -93.39%. cbdMD, Inc.'s return on equity of -47.18% beat Glaukos Corp.'s return on equity of -25.22%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.54.93% -$0.04 $9.6M GKOSGlaukos Corp.77.8% -$2.32 $762.7M -
What do Analysts Say About YCBD or GKOS?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 146.31%. On the other hand Glaukos Corp. has an analysts' consensus of $134.79 which suggests that it could grow by 11.28%. Given that cbdMD, Inc. has higher upside potential than Glaukos Corp., analysts believe cbdMD, Inc. is more attractive than Glaukos Corp..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 GKOSGlaukos Corp.10 0 1 -
Is YCBD or GKOS More Risky?
cbdMD, Inc. has a beta of 2.127, which suggesting that the stock is 112.722% more volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.259%.
-
Which is a Better Dividend Stock YCBD or GKOS?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or GKOS?
cbdMD, Inc. quarterly revenues are $5M, which are smaller than Glaukos Corp. quarterly revenues of $143.1M. cbdMD, Inc.'s net income of -$283.1K is higher than Glaukos Corp.'s net income of -$133.7M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.26x versus 13.65x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.26x -- $5M -$283.1K GKOSGlaukos Corp.13.65x -- $143.1M -$133.7M
-
Which has Higher Returns YCBD or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -5.64% compared to cbdMD, Inc.'s net margin of -255.85%. cbdMD, Inc.'s return on equity of -47.18% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.54.93% -$0.04 $9.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About YCBD or NBY?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 146.31%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could grow by 197.2%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than cbdMD, Inc., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is YCBD or NBY More Risky?
cbdMD, Inc. has a beta of 2.127, which suggesting that the stock is 112.722% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.246, suggesting its less volatile than the S&P 500 by 75.426%.
-
Which is a Better Dividend Stock YCBD or NBY?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $4.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or NBY?
cbdMD, Inc. quarterly revenues are $5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. cbdMD, Inc.'s net income of -$283.1K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.26x versus 1.10x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.26x -- $5M -$283.1K NBYNovaBay Pharmaceuticals, Inc.1.10x 5.05x $521K -$1.3M
-
Which has Higher Returns YCBD or SAVA?
Cassava Sciences, Inc. has a net margin of -5.64% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -47.18% beat Cassava Sciences, Inc.'s return on equity of -86.98%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.54.93% -$0.04 $9.6M SAVACassava Sciences, Inc.-- -$0.22 $81.6M -
What do Analysts Say About YCBD or SAVA?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 146.31%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 244.83%. Given that Cassava Sciences, Inc. has higher upside potential than cbdMD, Inc., analysts believe Cassava Sciences, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 SAVACassava Sciences, Inc.1 0 0 -
Is YCBD or SAVA More Risky?
cbdMD, Inc. has a beta of 2.127, which suggesting that the stock is 112.722% more volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -0.848, suggesting its less volatile than the S&P 500 by 184.779%.
-
Which is a Better Dividend Stock YCBD or SAVA?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or SAVA?
cbdMD, Inc. quarterly revenues are $5M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. cbdMD, Inc.'s net income of -$283.1K is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.26x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.26x -- $5M -$283.1K SAVACassava Sciences, Inc.2.69x -- -- -$10.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 11.61% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.92% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.18% over the past day.
